Találati lista | Tudóstér

001-es BibID:	BIBFORM064300
035-os BibID:	(cikkazonosító)e0158000 (WOS)000378212400066 (Scopus)84976863903
Első szerző:	Kalló Gergő (molekuláris biológus)
Cím:	Changes in the chemical barrier composition of tears in Alzheimer's disease reveal potential tear diagnostic biomarkers / Gergő Kalló, Miklós Emri, Zsófia Varga, Bernadett Ujhelyi, József Tőzsér, Adrienne Csutak, Éva Csősz
Dátum:	2016
ISSN:	1932-6203
Megjegyzések:	Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, with increasing prevalence affecting millions of people worldwide. Currently, only autopsy is able to confirm the diagnosis with a 100 % certainty, therefore, biomarkers from body fluids obtained by non-invasive means provide an attractive alternative for the diagnosis of Alzheimer`s disease. Global changes of the protein profile were examined by quantitative proteomics; firstly, electrophoresis and LC-MS/MS were used, thereafter, SRM-based targeted proteomics method was developed and applied to examine quantitative changes of tear proteins.Alterations in the tear flow rate, total tear protein concentration and composition of the chemical barrier specific to AD were demonstrated, and the combination of lipocalin-1, dermcidin, lysozyme-C and lacritin was shown to be a potential biomarker, with an 81 % sensitivity and 77 % specificity.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk chemical barrier Alzheimer's disease tear proteomics biomarker quantitative mass spectrometry SRM
Megjelenés:	Plos One. - 11 : 6 (2016), p. 1-14. -
További szerzők:	Emri Miklós (1962-) (fizikus) Varga Zsófia (1970-) (pszichiáter) Ujhelyi Bernadett (1981-) (szemész) Tőzsér József (1959-) (molekuláris biológus, biokémikus, vegyész) Csutak Adrienne (1971-) (szemész) Csősz Éva (1977-) (biokémikus, molekuláris biológus)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0045 TÁMOP Proteomika, Szemészet Kutatócsoport TÁMOP 4.2.4.A/2-11-1-2012-0001 TÁMOP TÁMOP-4.2.2.D-15/1/KONV-2015-0016 TÁMOP TÁMOP-4.2.2.B-15/1/KONV-2015-0001 TÁMOP National Brain Research Program KTIA_13_NAP-A-II/3 ME Egyéb Astellas Pharma Ltd. Fellowship Egyéb Lajos Szodoray Postdoctoral Fellowship Egyéb Janos Bolyai Postdoctoral Fellowship Egyéb
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM079023
035-os BibID:	(cikkazonosító)e0209157 (WOS)000453774100038 (Scopus)85058779848
Első szerző:	Kellermann Mónika (pszichiáter)
Cím:	Does the severity of depressive symptoms after stroke affect long-term survival? An 18-year follow-up / Mónika Kellermann, Roland Berecz, Dániel Bereczki
Dátum:	2018
ISSN:	1932-6203
Megjegyzések:	Objective We tested whether the severity of depressive symptoms in acute stroke and 4 years later are predictors of long-time survival. Method We evaluated the severity of stroke in 82 patients with acute stroke by the Barthel index, the Scandinavian Stroke Scale and the Orgogozo scale, and we also quantified the severity of depressive symptoms by the Beck and the Hamilton scales in the first week of stroke, in 1995. We re-evaluated the scales 4 years after stroke in 41 out of 48 survivors. We checked the survival status of the initial cohort 18 years after stroke. In the assessment Kaplan-Meier graphs were constructed and the outcomes between groups were compared with log-rank tests. Results Clinically important depressive symptoms (?10 on the Beck scale) was present in 16 patients (19,5%) with acute stroke one week after admission. Case fatality was 41% at 4 years and 84% at 18 years after stroke. Those patients who survived at 4 years were significantly younger (p<0,05). Depressive symptoms in acute stage were not independent predictor of the length of survival. More severe strokes were associated with more severe depressive symptoms 4 years after stroke. In the survival subgroup of patients, those who had more severe depression (?10 on the Beck scale) at 4 years, had shorter post-stroke survival than those with milder or no depression (Mann-Whitney test, p = 0.022; log-ranktest, p = 0.047). In multivariate analyses, adjusted for age, sex, stroke severity and the severity of depressive symptoms, age, sex and stroke severity remained the significant predictors of the length of survival.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Plos One. - 13 : 12 (2018), p. 1-11. -
További szerzők:	Berecz Roland (1970-) (pszichiáter szakorvos) Bereczki Dániel (1960-) (neurológus)
Pályázati támogatás:	KTIA-NAP-13-1-2013-0001 Egyéb TÁMOP-4.2.1.B-09/1/KMR TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM054457
035-os BibID:	Article ID: e106533
Első szerző:	Szabó Attila (molekuláris biológus, immunológus, filozófus)
Cím:	Psychedelic N,N-Dimethyltryptamine and 5-Methoxy- N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells / Attila Szabo, Attila Kovacs, Ede Frecska, Eva Rajnavolgyi
Dátum:	2014
ISSN:	1932-6203
Megjegyzések:	The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-inflammatory responses and immunosuppression in murine in vivo models. Since the details of these findings have not been elucidated so far, we studied the effects of the endogenous sigmar-1 ligands N,N-dimethyltryptamine (NN-DMT), its derivative 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and the synthetic high affinity sigmar-1 agonist PRE-084 hydrochloride on human primary monocyte-derived dendritic cell (moDCs) activation provoked by LPS, polyI:C or pathogen-derived stimuli to induce inflammatory responses. Co-treatment of moDC with these activators and sigma-1 receptor ligands inhibited the production of pro-inflammatory cytokines IL-1?, IL-6, TNF? and the chemokine IL-8, while increased the secretion of the anti-inflammatory cytokine IL-10. The T-cell activating capacity of moDCs was also inhibited, and dimethyltryptamines used in combination with E. coli or influenza virus as stimulators decreased the differentiation of moDC-induced Th1 and Th17 inflammatory effector T-cells in a sigmar-1 specific manner as confirmed by gene silencing. Here we demonstrate for the first time the immunomodulatory potential of NN-DMT and 5-MeO-DMT on human moDC functions via sigmar-1 that could be harnessed for the pharmacological treatment of autoimmune diseases and chronic inflammatory conditions of the CNS or peripheral tissues. Our findings also point out a new biological role for dimethyltryptamines, which may act as systemic endogenous regulators of inflammation and immune homeostasis through the sigma-1 receptor.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban psychedelics N,N-dimethyltryptamine 5-methoxy-N,N-dimethyltryptamine sigma-1 receptor innate immunity inflammation dendritic cell
Megjelenés:	Plos One. - 9 : 8 (2014), [12] p. -
További szerzők:	Kovács Attila Frecska Ede (1953-) (pszichiáter) Rajnavölgyi Éva (1950-) (immunológus)
Pályázati támogatás:	4.2.4. A/2-11-1-2012-0001 TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: